Literature DB >> 18486742

Head and neck cancer.

Athanassios Argiris1, Michalis V Karamouzis, David Raben, Robert L Ferris.   

Abstract

Most head and neck cancers are squamous cell carcinomas that develop in the upper aerodigestive epithelium after exposure to carcinogens such as tobacco and alcohol. Human papillomavirus has also been strongly implicated as a causative agent in a subset of these cancers. The complex anatomy and vital physiological role of the tumour-involved structures dictate that the goals of treatment are not only to improve survival outcomes but also to preserve organ function. Major improvements have been accomplished in surgical techniques and radiotherapy delivery. Moreover, systemic therapy including chemotherapy and molecularly targeted agents--namely, the epidermal growth factor receptor inhibitors--has been successfully integrated into potentially curative treatment of locally advanced squamous-cell carcinoma of the head and neck. In deciding which treatment strategy would be suitable for an individual patient, important considerations include expected functional outcomes, ability to tolerate treatment, and comorbid illnesses. The collaboration of many specialties is the key for optimum assessment and decision making. We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck.

Entities:  

Mesh:

Year:  2008        PMID: 18486742      PMCID: PMC7720415          DOI: 10.1016/S0140-6736(08)60728-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  143 in total

1.  Definitive radiotherapy for tonsillar squamous cell carcinoma.

Authors:  William M Mendenhall; Christopher G Morris; Robert J Amdur; Russell W Hinerman; Robert S Malyapa; John W Werning; Christopher D Lansford; Douglas B Villaret
Journal:  Am J Clin Oncol       Date:  2006-06       Impact factor: 2.339

2.  Quality of life and head and neck cancer: a 5 year prospective study.

Authors:  Helmut Abendstein; Mats Nordgren; Morten Boysen; Magnus Jannert; Ewa Silander; Marianne Ahlner-Elmqvist; Eva Hammerlid; Kristin Bjordal
Journal:  Laryngoscope       Date:  2005-12       Impact factor: 3.325

3.  Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment.

Authors:  L Mao; J S Lee; Y H Fan; J Y Ro; J G Batsakis; S Lippman; W Hittelman; W K Hong
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

4.  Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.

Authors:  Q T Le; K K Fu; S Kroll; J K Ryu; J M Quivey; T S Meyler; R M Krieg; T L Phillips
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-08-01       Impact factor: 7.038

Review 5.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

Review 6.  Elective and therapeutic selective neck dissection.

Authors:  Alfio Ferlito; Alessandra Rinaldo; Carl E Silver; Christine G Gourin; Jatin P Shah; Gary L Clayman; Luiz P Kowalski; Ashok R Shaha; K Thomas Robbins; Carlos Suárez; C René Leemans; Petra Ambrosch; Jesus E Medina; Randal S Weber; Eric M Genden; Phillip K Pellitteri; Jochen A Werner; Eugene N Myers
Journal:  Oral Oncol       Date:  2005-06-23       Impact factor: 5.337

7.  Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial.

Authors:  J M Bachaud; E Cohen-Jonathan; C Alzieu; J M David; E Serrano; N Daly-Schveitzer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-12-01       Impact factor: 7.038

8.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

9.  Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial.

Authors:  R P Morton; F Rugman; E B Dorman; P J Stoney; J A Wilson; M McCormick; A Veevers; P M Stell
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation?

Authors:  Andrew Simpson Jones; Brian Fish; John Eugene Fenton; David John Husband
Journal:  Head Neck       Date:  2004-02       Impact factor: 3.147

View more
  653 in total

1.  Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.

Authors:  Amal Ahmed-Fouad Halim; Hanan Ahmed Wahba; Hend Ahmed El-Hadaad; Ahmed Abo-Elyazeed
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

2.  Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma.

Authors:  K A Skorupski; T G O'Brien; T Guerrero; C O Rodriguez; M R Burns
Journal:  Vet Comp Oncol       Date:  2011-03-08       Impact factor: 2.613

3.  Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study.

Authors:  Scott M Langevin; Devin C Koestler; Brock C Christensen; Rondi A Butler; John K Wiencke; Heather H Nelson; E Andres Houseman; Carmen J Marsit; Karl T Kelsey
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

4.  Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target.

Authors:  Pratima Tripathi; Pachiyappan Kamarajan; Bagganahalli S Somashekar; Neil MacKinnon; Arul M Chinnaiyan; Yvonne L Kapila; Thekkelnaycke M Rajendiran; Ayyalusamy Ramamoorthy
Journal:  Int J Biochem Cell Biol       Date:  2012-06-26       Impact factor: 5.085

5.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

6.  Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery.

Authors:  Ashwin A Bhirde; Vyomesh Patel; Julie Gavard; Guofeng Zhang; Alioscka A Sousa; Andrius Masedunskas; Richard D Leapman; Roberto Weigert; J Silvio Gutkind; James F Rusling
Journal:  ACS Nano       Date:  2009-02-24       Impact factor: 15.881

Review 7.  Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas.

Authors:  Görkem Eskiizmir
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-09-01

Review 8.  Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Authors:  Paulina Kozakiewicz; Ludmiła Grzybowska-Szatkowska
Journal:  Oncol Lett       Date:  2018-03-20       Impact factor: 2.967

Review 9.  PPARγ in head and neck cancer prevention.

Authors:  Mauricio Burotto; Eva Szabo
Journal:  Oral Oncol       Date:  2014-01-13       Impact factor: 5.337

10.  DNA microarray reveals ZNF195 and SBF1 are potential biomarkers for gemcitabine sensitivity in head and neck squamous cell carcinoma cell lines.

Authors:  Min-Hui Zhu; Shun-Long Ji; Cai-Yun Zhang; Long Cui; Lei Xiong; Hong-Liang Zheng
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.